Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Prepare Now to Sell Your Medical Practice

Steven M. Harris, Esq.  |  August 15, 2017

Selling a medical practice can be a lucrative endeavor. One of the most important phases of any sale transaction is the due diligence process. During this phase, a potential buyer and their advisors have the opportunity to examine the seller’s books, records and files in great detail to ensure that the buyer is comfortable purchasing…

HSCT for Severe Autoimmune Diseases

HSCT for Severe Autoimmune Diseases

Ruth Jessen Hickman, MD  |  August 14, 2017

Despite the innovations of new biologics and disease-modifying anti-rheumatic drugs, a large unmet need remains for patients with rheumatic autoimmune disease. Treatment remains limited for many conditions, including for conditions with a dim prognosis, such as systemic sclerosis.1 One promising treatment avenue is hematopoietic stem-cell transplantation (HSCT). Here, we provide background on HSCT for severe…

Investments in Legislative Advocacy Pay Off for Ohio Association of Rheumatology

Gretchen Henkel  |  August 14, 2017

Like many other state rheumatology associations, the Ohio Association of Rheumatology (OAR) has recently been actively advocating for patient care at the state legislative level. The most recent example of OAR’s efforts included an Advocacy Day on May 4, when members met with state legislators to discuss topics of interest. It was the fourth such…

In Memoriam: Dr. H. Ralph Schumacher Jr.

Simon M. Helfgott, MD  |  August 14, 2017

Our esteemed colleague, H. Ralph Schumacher Jr., MD, professor emeritus and former acting chief of rheumatology at the University of Pennsylvania School of Medicine, and section chief of rheumatology at the VA Medical Center in Philadelphia, died at his home on July 30 from complications of amyotrophic lateral sclerosis. Dr. Schumacher was a true giant…

TNF Stabilizes Inflammatory RNA in Synoviocytes

Lara C. Pullen, PhD  |  August 14, 2017

A recent study has helped researchers gain insight into the genome-wide regulation of mRNA stability in RA fibroblast-like synoviocytes (FLS). Chronic exposure of FLS to tumor necrosis factor appears to increase mRNA stability, enhancing the expression of inflammatory genes and the perpetuation of synovitis…

Rheumatology Drug Updates: Opana ER Painkiller Pulled from U.S. Market; Upadacitinib to Treat RA, and More

Michele B. Kaufman, PharmD, BCGP  |  August 13, 2017

Opana ER Pulled from U.S. Market Last month, the U.S. Food and Drug Administration (FDA) asked Endo Pharmaceuticals to remove oxymorphone hydrochloride extended release (Opana ER) from the U.S. market due to public health consequences related to abuse. The agency has concerns that the risks presented by the treatment do not outweigh its benefits.1 On…

University of Nebraska Division of Rheumatology and Immunology Makes Education, Clinical Research Top Priorities

Gretchen Henkel  |  August 13, 2017

When it was created in 1982, the Division of Rheumatology and Immunology at the University of Nebraska Medical Center comprised one-and-a-half rheumatologists: its founder, Lynell W. Klassen, MD, MACR, and Gerald Moore, MD, who later received formal training at the NIH and now serves as senior associate dean for academic affairs. Thirty-five years later, the…

Fellows' Forum Case Report: Hemophagocytic Lymphohistiocytosis

Fellows’ Forum Case Report: Hemophagocytic Lymphohistiocytosis

Anita Laloo, MB, BS, MPH, German Pihan, MD, & Robert H. Shmerling, MD  |  August 13, 2017

The patient was a 48-year-old woman who saw her primary care physician for a flu-like illness three months prior to admission. Her symptoms initially improved, but recurred one month later; she was treated symptomatically, and again symptoms resolved. Two months later, she presented to an outside facility’s emergency department with fever to 103ºF, with associated…

How to Ask for a Raise

Karen Appold  |  August 13, 2017

Whether you’re a rheumatologist or a rheumatology health professional, unless you are self-employed, the time will come when you start thinking it may be time to ask for a raise. The thought of asking for a raise likely conjures up anything but warm and fuzzy feelings, but if you do it at the right time—and…

Aims Review Committee Helps Rheumatology Researchers Craft Grant Proposals

Elizabeth Hofheinz, MPH, MEd  |  August 13, 2017

There you are, working steadily away on your next manuscript. The ideas are flowing. You’ve hit your stride. Nothing can stop you now—nothing, that is, except a colleague who shows up at your desk with a 20-page grant proposal. “Do you mind?” he asks. Across academia the problem is the same—too few hours in the…

  • « Previous Page
  • 1
  • …
  • 405
  • 406
  • 407
  • 408
  • 409
  • …
  • 816
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences